StockNews.com upgraded shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) from a hold rating to a buy rating in a research note released on Wednesday morning. Separately, Piper Sandler ...

Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...

BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organic ...

BD announced its board of directors has unanimously ... Try Now>> See the top stocks recommended by analysts >> Read More on BDX: Becton, Dickinson NewsMORE Related Stocks Indices Commodities ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson (BDX) stock slid 3% after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate entities.